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The therapeutic application of human induced pluripotent stem cells (hiPSCs) for cartilage
regeneration is largely hindered by the low yield of chondrocytes accompanied by unpre-
dictable and heterogeneous off-target differentiation of cells during chondrogenesis. Here, we
combine bulk RNA sequencing, single cell RNA sequencing, and bioinformatic analyses,
including weighted gene co-expression analysis (WGCNA), to investigate the gene reg-
ulatory networks regulating hiPSC differentiation under chondrogenic conditions. We identify
specific WNTs and MITF as hub genes governing the generation of off-target differentiation
into neural cells and melanocytes during hiPSC chondrogenesis. With heterocellular signaling
models, we further show that WNT signaling produced by off-target cells is responsible for
inducing chondrocyte hypertrophy. By targeting WNTs and MITF, we eliminate these cell
lineages, significantly enhancing the yield and homogeneity of hiPSC-derived chondrocytes.
Collectively, our findings identify the trajectories and molecular mechanisms governing cell
fate decision in hiPSC chondrogenesis, as well as dynamic transcriptome profiles orches-
trating chondrocyte proliferation and differentiation.
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Osteoarthritis (OA) is a debilitating joint disease char-acterized by cartilage degeneration and pathologicremodeling of other joint tissues. Cartilage has limited
intrinsic healing capacity, motivating the application of stem cells
for regenerative therapies. In this regard, the advent of
human induced pluripotent stem cells (hiPSCs) has served as a
major breakthrough toward cartilage regenerative therapies and
in vitro disease modeling for OA drug discovery1. However, the
development of protocols to consistently differentiate hiPSCs into
chondrocytes remains challenging. Early studies reported that
chondrocytes can be generated from hiPSCs via embryoid body
formation followed by monolayer expansion of mesodermal cells
and three-dimensional cell pellet culture in chondrogenic
induction medium2,3. Despite some success, this approach was
proven difficult to reproduce across different iPSC lines, poten-
tially due to variability in lots of fetal bovine serum (FBS) gen-
erally used for cell expansion. Thus, recent strategies have sought
to use serum-free and chemically defined medium4–6. By cou-
pling inductive and repressive signals required for mesoderm
specification in embryonic development7, we established a step-
wise hiPSC chondrogenic differentiation protocol that was vali-
dated with multiple hiPSC lines and in several laboratories8.
An important consideration in the differentiation process of
hiPSCs is that they are considered to be in a primed pluripotent
state with increased genome-wide DNA methylation compared to
ground state naïve pluripotent cells, such as preimplantation blas-
tocysts9. Therefore, even directed differentiation of hiPSCs can lead
to the unpredictable formation of off-target cell populations.
However, the gene regulatory networks (GRNs) leading to on- or
off-target differentiation of hiPSCs, as well as the effect of the
undesired cells on hiPSC chondrogenesis (i.e., heterocellular sig-
naling), remain to be elucidated, particularly at the single-cell level.
Here, we apply bulk RNA sequencing (bulk RNA-seq) and
single-cell RNA sequencing (scRNA-seq) throughout the process
of mesodermal and chondrogenic differentiation of hiPSCs to
map the dynamics of gene expression. By exploiting single-cell
transcriptomics, we confirm the mesodermal and chondrogenic
differentiation of hiPSCs in addition to identifying the GRNs and
critical hub genes regulating the generation of heterogenous off-
target cells. We demonstrate that the homogeneity of hiPSC
chondrogenesis can be significantly improved by inhibiting the
molecular targets WNTs and MITF. In summary, this study
develops and validates an enhanced hiPSC chondrogenic differ-
entiation protocol.
Results
Bulk RNA-seq indicates successful differentiation of hiPSCs.
Previously, we reported a robust differentiation protocol that can
drive hiPSCs toward a chondrogenic lineage via the paraxial
mesoderm7 (Supplementary Fig. 1A, B). To determine tran-
scriptome profiles over the course of differentiation, three inde-
pendent hiPSCs lines (ATCC, BJFF, and STAN) were collected
for bulk RNA-seq at various stages (Fig. 1A). Principal compo-
nent analysis (PCA) reveals that the three hiPSC lines follow
similar mesodermal and chondrogenic differentiation trajectories
(Fig. 1B, C). Analysis of differentially expressed genes (DEGs)
between each stage revealed upregulation of stage-specific mar-
kers. For example, T-box transcription factor T (TBXT) and mix
paired-like homeobox (MIXL1) were upregulated at the anterior
primitive streak (anterior PS) stage compared to hiPSCs10
(Fig. 1D; Supplementary Table 1). Markers representing meso-
dermal derivatives including T-box 6 (TBX6), UNC homeobox
(UNCX), and paired box 9 (PAX9) were upregulated sequentially
at the stages of paraxial mesoderm, early somite, and sclerotome,
respectively (Fig. 1D; Supplementary Fig. 1C).
Chondrogenic markers such as matrilin 4 (MATN4), aggrecan
(ACAN), collagen type VI alpha 3 chains (COL6A3), collagen type
IX alpha 1 chain (COL9A1), and SRY-box 6 and 9 (SOX6 and
SOX9) were upregulated as early as at day 7 (d7), while the
expression of collagen type II alpha 1 chain (COL2A1) was
increased at d21 (Fig. 1E; Supplementary Table 2). Interestingly,
microRNA-302a (MIR302A), reportedly downregulated in
osteoarthritic chondrocytes, had enhanced expression in d28
pellets11. Neuronal differentiation 4 (NEUROD4), a gene encod-
ing a transcriptional activator essential for neuronal differentia-
tion, had increased expression in d14 pellets12.
In vitro characterization of hiPSC-derived chondrocytes. While
temporal expression of chondrogenic markers such as SOX9 and
COL2A1 were upregulated in unique hiPSC lines, both the
hypertrophic chondrocyte marker collagen type X alpha 1 chain
(COL10A1) and osteogenic marker collagen type I alpha 1 chain
(COL1A1) also exhibited increased expression over time
(Fig. 2A). It is important to note that COL1A1 is also a marker
for fibrous tissues, perichondrium, and many other cell types. The
d28 pellet matrix also demonstrated rich proteoglycan staining
using Safranin-O (Saf-O) as well as intense labeling for COL2A1
and COL6A1 by immunohistochemistry (IHC). However, little
labeling for COL10A1 and COL1A1 was observed despite
increased gene expression of COL10A1 and COL1A1 at later time
points (Fig. 2B). Gene ontology (GO) enrichment analysis of the
genes using R package GAGE was performed13. Significantly
upregulated GO terms in Biological Process highlighted skeletal
system and cartilage development (Supplementary Fig. 2A).
GAGE analysis also revealed that 134 out of the 205 genes defined
by cartilage development (GO:0051216) were significantly
increased. Interestingly, in addition to upregulated SOX5, 6, and
9, which are known to be master transcription factors (TFs)
governing chondrogenesis, we also observed several WNTs,
including WNT2B, had increased gene expression at different
stages during differentiation (Fig. 2C).
To determine the phenotype of hiPSC-derived cartilage, we
projected our bulk RNA-seq data and publicly available sequencing
datasets of primary chondrocytes from a variety of cartilaginous
tissues and chondrocytes derived from human mesenchymal stem
cells (hMSCs) in a PCA plot (Fig. 2D)14. We found that hiPSC-
derived chondrocytes demonstrated a similar phenotype to
embryonic limb bud chondrocytes.
In vivo characterization of hiPSC-derived chondrocytes. To
determine whether hiPSC-derived chondrocytes could maintain
their phenotype in vivo, we implanted d14 pellets subcutaneously
in the dorsal region of immunodeficient NSG (NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ) mice (Supplementary Fig. 2B). The d14 pellets
represented the earliest time point when a chondrocyte-like
phenotype was observed in vitro. After 14 days of implantation,
pellets were harvested and found to retain a cartilage phenotype,
with rich proteoglycan and COL2A1 labeling. No endochondral
ossification was observed during this relatively short-term
implantation period in our study.
To test whether hiPSC-derived chondrocytes can retain their
phenotype within the joint, we created an osteochondral defect in
the femoral groove of the mouse (Fig. 2E). Due to the small size of
the mouse knee, the osteochondral defect model here also
involves a growth plate defect. The defect was either left empty as
a non-repair control group or filled with a d14 pellet. Defects left
untreated did not exhibit any repair with hyaline cartilage, and
only fibrotic tissue was observed. However, defects with pellet
implantation demonstrated enhanced repair of the focal cartilage
lesion, which was filled with cartilaginous matrix rich in Saf-O
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Fig. 1 DEGs of mesodermal and chondrogenic differentiation of three hiPSC lines by bulk RNA-seq. A Schematic of the chondrogenic differentiation
protocol for hiPSCs. B, C PCA indicates that three unique hiPSC lines followed similar differentiation trajectories. D, E DEGs averaged from three unique
hiPSC lines at each stage of differentiation, respectively. Each column of the heatmap represents a comparison between two stages/time points, and each
gene presented was assigned a colored dot (following the gene label). The color of the dot matches the color of the timepoint label on the left side of the
heatmap. When the color of a gene label and a timepoint label match, that gene was significantly upregulated at the corresponding time points.
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staining at both 14 and 28 days post implantation. While this
finding provides proof-of-concept of the maintenance of the
chondrogenic phenotype over 28 days, future studies may wish to
investigate cell fate and implant properties after long-term
implantation.
scRNA-seq mapping of cellular heterogeneity. Although our
protocol generates a predominantly chondrocyte-like population
as shown by IHC and bulk RNA-seq (Fig. 2B), we often observed
non-chondrocyte populations and occasional focal accumulation
of black-pigmented regions on the surface of the pellets
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(Supplementary Fig. 2C, D). These results suggest the presence of
off-target differentiation, prompting us to seek their cellular
identities. To dissect this cellular heterogeneity, nine samples
from the STAN cell line at various differentiation time points
were collected for scRNA-seq (Fig. 3A). Detailed cell numbers
and median genes per cell for each stage are listed in Supple-
mentary Table 5 (see “Methods” for quality control steps and
criteria).
Sequencing of mixed-species ensured a low cell multiplet rate
(2.7%) (Supplementary Fig. 3A). To verify the reproducibility of
the differentiation, two batches of d28 samples were collected
from independent experiments for scRNA-seq. Canonical
correlation analysis (CCA) was used to align cells from the two
batches15 (Supplementary Fig. 3B). The cells in the same cluster
from different batches exhibited a high correlation in their gene
expression (Spearman’s rank coefficient rs > 0.87 for all clusters)
(Supplementary Fig. 3C). Furthermore, genes that were highly
conserved in one particular cluster showed similar expression
patterns in the clusters from distinct batches, suggesting that our
differentiation is highly reproducible (Supplementary Fig. 3D).
Lineage bifurcation in hiPSC differentiation trajectory. We
used the Monocle2 R package to reconstruct the differentiation
trajectory from the stage of hiPSCs to d42 chondrocytes with a
total of 19,195 cells that passed quality control (Fig. 3B)16. While
cells following chondrogenic fate expressed chondrocyte markers,
including ACAN, COL2A1, SOX9, and cartilage oligomeric matrix
protein (COMP), we found one major branchpoint, diverting cell
fate toward neural lineage with the expression of neural cell
markers such as nestin (NES), orthodenticle homeobox 2 (OTX2),
SOX2, and WNT3A (Fig. 3C). Other neural cell markers such as
OTX1 and PAX6 were also enriched in this branch (Supple-
mentary Fig. 3E). The off-target cell differentiation toward neu-
rogenic lineage confirmed our findings of increased NEUROD4 in
the bulk RNA-seq data.
To explore distinct cell populations at each stage, scRNA-seq
data were subjected to unsupervised clustering and visualized
using t-distributed stochastic neighbor embedding (tSNE) plots
(Fig. 3D). By comparing DEGs with signature genes of cell types
in the literature and GO term analyses, we annotated broad cell
populations by combining clusters expressing similar marker
genes. For example, 2 of 7 clusters identified at the chondropro-
genitor (Cp) stage not only had high expression levels of SOX4
and SOX9 but were also enriched in several markers resembling
neural crest cells including PAX3 and forkhead box D3 (FOXD3)
(Supplementary Fig. 3F)17. Therefore, these two clusters were
assigned to a broad cell population referred to as neural crest
cells. Similarly, 4 clusters at the Cp stage exhibited markers of the
neural lineage including SOX2, OTX1/2, and PAX6, and thus
were annotated as neurogenic lineage cells, while PRRX1,
COL1A1, and COL3A1 are known markers for mesenchyme
(Supplementary Fig. 3G)18. Similar major cell populations were
also observed in d1 and d3 pellets, and it appeared that the
percentage of chondrogenic cells increased in d7 while there was a
decreased percentage of neural crest cells over time (Supplemen-
tary Fig. 3H, I).
Of note, a cluster with high expression of melanocyte-inducing
TF (MITF) was observed in d7 and d14 pellets. MITF is a master
TF regulating the development of melanocytes, cells that produce
melanin (i.e., pigment)19. IHC of the pellets labeling for NES and
MITF further confirmed the presence of neural cells and
melanocytes (Supplementary Fig. 3J), suggesting that the focal
black dots observed at the surface of pellets are likely to be the
pigment accumulation in melanocytes. Furthermore, mesenchy-
mal cells in d14 pellets expressed several conventionally
recognized MSC markers (Supplementary Fig. 3K). Nevertheless,
as distinct subtypes of hiPSC-derived chondrocytes and off-target
cells were defined primarily based on marker genes, the complete
functionality of these populations requires future investigation.
WGCNA identifies GRNs of neurogenesis and melanogenesis.
Next, we aimed to improve hiPSC chondrogenesis by decreasing
off-target differentiation. We performed weighted gene co-
expression network analysis (WGCNA) to reconstruct GRNs
and identify the hub genes that modulate neurogenesis and
melanogenesis20. scRNA-seq data of d14 pellets (with a total of
2148 cells and 3784 genes) were used for this computation due to
the earliest presence of both chondrogenic and off-target popu-
lations detected. Five major gene modules (each containing >150
genes) were identified and based on GO enrichment analyses,
they were categorized into cell division, cilium movement and
assembly, skeletal system development, nervous system develop-
ment, and melanin biosynthetic process. The genes in the mod-
ules of nervous system development and melanin biosynthetic
process were then used to build corresponding GRNs and sub-
networks by Cytoscape, while hub genes were determined by
degree (node connectivity), weight (association between two
genes), and betweenness centrality (BC) measure of the network
(Fig. 3E and Supplementary Fig. 4A–C)21. In the GRN of neu-
rogenesis, WNT4 was strongly associated with several TFs reg-
ulating neural differentiation. We also observed that WNT2B was
associated with both MITF and ETS variant 1 (ETV1), a gene
whose activity has been reported to positively regulate MITF22.
Inhibition of WNT signaling enhances hiPSC chondrogenesis.
As WNTs were identified as essential genes in the off-target cells,
we hypothesized that inhibition of WNT signaling may improve
hiPSC chondrogenesis by decreasing undesired cell populations. It
is known that WNTs are required to properly specify somites from
pluripotent cells23. Therefore, we administrated Wnt-C59 (C59), a
WNT inhibitor, at either the Cp stage and/or during the chon-
drogenic pellet culture (i.e., four different inhibition regimens,
Fig. 4A). Chondrocyte homogeneity, as indicated by Saf-O staining,
was increased if WNT signaling was inhibited during pellet culture
(Fig. 4B). This finding was reflected by the increased production of
glycosaminoglycans per cell (GAG/DNA ratio) in the group
receiving C59 during the pellet culture (Fig. 4C). However, inhi-
biting WNTs at the Cp stage severely impaired chondrogenesis.
Fig. 2 In vitro and in vivo characterization of hiPSC-derived chondrocytes. A Temporal gene expression of chondrogenic markers SOX9 and COL2A1,
hypertrophic marker COL10A1, and osteogenic marker COL1A1. B Pellets showed enriched Saf-O, COL2A1, and COL6A1 staining. Most COL1A1 staining
(green arrowheads) was located at the edge of the pellets, while faint COL10A1 (yellow arrowheads) was observed. Left column scale bar= 400 µm. Right
column scale bar= 200 µm. Inset scale bar= 50 µm. The experiment was repeated three times with similar results. C Heatmap of 134 significantly
upregulated genes identified in GO term cartilage development (GO:0051216). Genes in red font are either TFs or transcription regulators. D hiPSC-derived
chondrocytes exhibit a similar phenotype to embryonic limb bud chondrocytes. E hiPSC-derived chondrocytes repaired osteochondral defects in the
cartilage of mouse knee joints and retained a chondrocyte phenotype 28 days post implantation. n= 3 mice per group. Top row scale bar= 500 µm.
Bottom row scale bar= 100 µm.
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Fig. 3 scRNA-seq and WGCNA reveal neural cells and melanocytes as off-target cells. A scRNA-seq was performed at hiPSC, Sclerotome, Cp, and six
chondrogenic pellet time points. B Reconstruction of differentiation trajectory reveals an off-target lineage bifurcation toward neural cells. A total of 19,195
cells that passed quality control from the stage of hiPSC to d42 chondrogenic pellet were used to reconstruct the differentiation trajectory. C Chondrogenic
markers were enriched in the chondrogenic branch, while neurogenic markers were observed in the branch of neurogenesis. D Annotated cell populations
at different time points during hiPSC chondrogenesis. Cells that passed quality are used for tSNE plots; Cp: 1888 cells, d1: 2216 cells, d7: 1200 cells, d14:
2148 cells, d28: 1271 cells, and d42: 1328 cells. E WGCNA and GO term analysis identified WNT4 as a hub gene of neurogenesis while WNT2B was highly
associated with melanocyte development. scRNA-seq data of d14 pellets (with a total of 2148 cells and 3784 genes) was used for this computation.
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Fig. 4 WNT inhibition during pellet culture enhanced homogeneity of hiPSC chondrogenesis. A Experimental scheme of WNT inhibition. B C59
treatment during pellet culture enhanced Saf-O staining and decreased off-target cells (yellow arrowheads) as compared to other WNT inhibition culture
regiments. Top row scale bar= 400 µm. Bottom row scale bar= 200 µm. The experiment was performed twice with similar results. C Pellets treated with
C59 in only pellet culture exhibited an increased GAG/DNA ratio compared to pellets treated with other culture regiments. *p= 0.00001 at d28. #p=
0.0228 at d42. Mean ± SEM. n= 4 pellets per group. Statistical significance was determined by one-way ANOVA with Tukey’s post hoc test at a specific
time point. D C59 significantly decreased, but WNT3A significantly increased, CD146+/CD166+/CD45− progenitors at the Cp stage. Different letters are
significantly different (a vs. b, p= 0.0005; a vs. c, p= 0.0021; b vs. c, p= 0.0001). Mean ± SEM. n= 3 per group (independent experiment). Statistical
significance was determined by one-way ANOVA with Tukey’s post hoc test. E RNA-FISH of d28 pellets showing C59-treated pellets had decreased
WNT3A and WNT4 labeling (green) but more homogenous COL2A1 distribution (red) in the pellets. Scale bar= 200 µm. The experiment was performed
twice with similar results.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20598-y ARTICLE
NATURE COMMUNICATIONS |          (2021) 12:362 | https://doi.org/10.1038/s41467-020-20598-y | www.nature.com/naturecommunications 7
Mesenchymal cells that are positive for CD146 and CD166 are
proposed to be putative Cps due to their robust chondrogenic
potential24. Flow cytometric analysis showed that C59 treatment
largely decreased the percentage of CD146/CD166+ cells, while
WNT3A supplementation increased this population at the Cp stage
(Fig. 4D). Similar results were observed using two additional hiPSC
lines (ATCC and BJFF) (Supplementary Fig. 4D–G). Interestingly,
pellets derived from hMSCs with WNT inhibition also exhibited
increased Saf-O staining (Supplementary Fig. 4H, I). In addition,
hiPSC pellets receiving combined administration of C59 and
ML329 (ML), an MITF antagonist, also exhibited enhanced chon-
drocyte homogeneity compared to standard TGF-β3 treatment
(Supplementary Fig. 4G).
RNA fluorescence in situ hybridization (RNA-FISH) labeling
of WNTs and COL2A1 within d28 pellets indicated that although
some labeling could be detected in the center of the pellets, most
WNTs were located in the perichondral layer, consistent to the
inhomogeneous cell populations observed via IHC staining.
Furthermore, C59-treated pellets showed a more homogenous
distribution of COL2A1 RNA-FISH labeling vs. TGF-β3-treated
pellets (Fig. 4E and Supplementary Fig. 5).
scRNA-seq confirms WNT inhibition enhances chondrogen-
esis. To determine how WNT inhibition altered cell populations
in chondrogenesis and to identify chondrocyte subpopulations,
pellets treated with C59 were analyzed using scRNA-seq with a
total of 14,683 cells from the stage of hiPSC, Cp as well as d7, d14,
d28, and d42 C59-treated pellets (Fig. 5A, B). We found the C59-
treated pellets comprised two major cell populations: mesench-
yme and chondrocytes. Mesenchyme exhibited high expression of
actin (ACTA2), PRRX1, COL1A1, and COL3A1. Most impor-
tantly, neural cells and melanocytes were significantly decreased
with WNT inhibition. The differentiation trajectory of C59-
treated chondrogenesis was reconstructed, using scRNA-seq
datasets of hiPSC and Cp stages from the previous sequencing
(since they did not involve C59 intervention) (Fig. 5C). Com-
pared to the trajectory built from TGF-β3-treated pellets, C59-
treated pellets exhibited little, if any, neurogenic markers, but
showed enriched expression for chondrogenic markers (Fig. 5D).
In pseudotime analysis, we found that C59-treatment led to
earlier induction of ACAN expression, higher levels of COL2A1
and SOX9 expression, and an earlier decrease in SOX2 expression
as compared to pellets treated with TGF-β3 alone (Supplementary
Fig. 6A).
Chondrocytes in C59-treated pellets comprised several sub-
populations as identified by multiple CCA alignment of d7-d42
timepoints with a total of 7997 cells (Fig. 5E, F, and
Supplementary Fig. 6B, C), including one mesenchymal popula-
tion and four conserved chondrocyte subsets with enriched
COL2A1 and SOX9 expression. The chondrocyte subset enriched
in cell cycling markers, such as high mobility group box 2 and
cyclin-dependent kinase 1 (HMGB2/CDK1+), was defined as
proliferating chondrocytes25. The second chondrocyte subset was
enriched in IGF-binding protein-5 (IGFBP5). It has been
previously reported that IGFBP5 is highly upregulated in the
early differentiating stage26. Hence, the IGFBP5+ chondrocyte
subset was defined as a population of early differentiating
chondrocytes. The third chondrocyte subset expressed leukocyte
cell-derived chemotaxin 1, epiphycan, and frizzled-related protein
(LECT1/EPYC/FRZB+) and had the highest levels of COL2A1 and
ACAN expression among other chondrocyte subsets. Therefore,
the LECT1/EPYC/FRZB+ chondrocyte subset was defined as a
population of early mature chondrocytes. Finally, we identified a
unique chondrocyte subset expressing interferon (IFN)-related
genes including ISG15 ubiquitin-like modifier, interferon-alpha
inducible protein 6, and MX dynamin-like GTPase 1 (ISG15/IFI6/
MX1+). We observed that 4.6% of ISG15/IFI6/MX1+ chondro-
cytes co-expressed terminal hypertrophic differentiation markers
VEGFA and MMP13; thus, we defined the ISG15/IFI6/MX1+
chondrocyte subset as mature-hypertrophic chondrocytes (Sup-
plementary Fig. 6D).
At early timepoint d7, HMGB2/CDK1+ proliferating chon-
drocytes was the main cell population (44.5%) within the pellets
(Supplementary Fig. 6C). Interestingly, this population also had
the highest numbers of BMPR1B/ITGA4 double-positive cells, a
rare osteochondral progenitor population found in articular
cartilage (Supplementary Fig. 6E, F)14. When proliferating
chondrocytes differentiated toward maturity, potentially facili-
tated by IGFBP526, IGFBP5+ early differentiating chondrocytes
and LECT1/EPYC/FRZB+ early mature chondrocytes became
dominant (Supplementary Fig. 6C). The enriched expression of
FRZB, which encodes a secretory WNT inhibitor, in early mature
chondrocytes might help stabilize this population by further
antagonizing WNT signaling in addition to C59 treatment
(Supplementary Fig. 6G). As LECT1/EPYC/FRZB+ chondrocytes
had the highest levels of COL2A1 and ACAN expression, we
investigated the DEGs of this particular population at various
time points (Fig. 5G). Among several early chondrogenic
markers and osteogenic markers, COL1A2 and IGFBP7 exhibited
biphasic upregulation at both early and later time points of
chondrogenesis.
The percentage of ISG15/IFI6/MX1+ mature-hypertrophic
chondrocytes greatly increased at d28 (Supplementary Fig. 6C).
Although the downstream IFN regulatory molecules including
STAT1 and PML were elevated in this population, we could not
detect any type of IFNs which were conventionally believed to be
the activators of IFN pathways (Supplementary Fig. 6H). Instead,
we observed that IGFBP3 was enriched in ISG15/IFI6/MX1+
chondrocytes, whereas IGFBP5 was highly expressed in early
differentiating chondrocytes. In line with the results of previous
studies, we also observed that IGFBP3 inhibited expression of
FOS (C-FOS), a possible driver of chondrocyte hypertrophy when
it dimerizes with JUN (AP-1) (Supplementary Fig. 6I)27. This
result may provide some explanations for the finding that ISG15/
IFI6/MX1+ chondrocytes had variable expression levels of
hypertrophic chondrocyte markers (Supplementary Fig. 6J)28.
During chondrogenic culture, pellets were generally sur-
rounded by a fibrous layer, resembling the cartilage anlage
enclosed by fibroblastic cells (i.e., perichondrium). To determine
if the mesenchyme (i.e., ACTA2/PRRX1/COL1A1+ cells) identi-
fied in pellets and the mesenchyme (i.e., PRRX1+ cells) identified
at the Cp stage (monolayer culture) were similar to the
perichondrium, we benchmarked these mesenchymal cells, as
well as various chondrocyte subpopulations, against previously
reported markers of perichondrial cells in rats and humans
(Supplementary Fig. 7)29,30. We found that ACTA2/PRRX1/
COL1A1+ cells in pellets, but not PRRX1+ cells at the Cp stage,
were enriched in genes of perichondrium, suggesting that the
mesenchymal population at the Cp stage and the mesenchymal
population in pellets had distinct phenotypes, despite their shared
mesenchymal genes such as COL1A1 and COL3A1. The scRNA-
seq data of C59-treated pellets were then used to reconstruct the
GRN of hiPSC chondrogenesis with minimal presence of off-
target cells as shown by WGCNA (Supplementary Fig. 8A).
Differential gene expression profiles after C59 treatment. Three
major conserved populations were identified after CCA alignment
of the d14 cells with or without C59 treatment (a total of 5224
cells analyzed): proliferative cells, mesenchyme enriched, and
chondrocytes (Fig. 6A, B). C59-treated pellets contained more
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Fig. 5 scRNA-seq of pellets with WNT inhibition shows improved chondrogenesis. A scRNA-seq was performed on the pellets with WNT inhibition.
B Chondrocytes and mesenchymal cells were two major populations in C59-treated pellets. Cells that passed quality control were used for tSNE plots; hiPSC:
4798 cells, Cp: 1888 cells, d7: 1682 cells, d14: 3076 cells, d28: 1756 cells, and d42: 1483 cells. C Differentiation trajectory of C59-treated pellets. scRNA-seq
data with a total of 14,683 cells from the stage of hiPSC, Cp as well as d7, d14, d28, and d42 C59-treated pellets were used to reconstruct the differentiation
trajectory. D C59-treated pellets exhibited decreased neurogenic markers but increased chondrogenic markers. EMultiple CCA alignment of d7–d42 pellets.
A total of 7977 cells from d7–d42 timepoints of C59-treated pellets were used to perform CCA alignment. F Dynamic changes in gene expression and
percentages of chondrocyte subpopulations over time. G Heat map of top 20 DEGs at each timepoint for LECT1/EPYC/FRZB+ early mature chondrocytes.
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mesenchyme and chondrocytes at d14, while non-C59-treated
(i.e., TGF-β3 only) pellets had more proliferative cells at the same
time point (Fig. 6C). Pellets with only TGF-β3 treatment not only
showed elevated expression of MITF but also had more neural
cells which were clustered in proliferative cells (Fig. 6D). Chon-
drocytes and proliferative cells exhibited similar profiles of
upregulated and downregulated DEGs. For instance, both cell
populations showed upregulated expression of COL2A1 and
JUNB, while exhibiting decreased expression of SOX4 and several
ribosomal genes (Supplementary Fig. 8B). Interestingly, FRZB
was only upregulated in the chondrocyte population upon C59
treatment.
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At d28, pellets treated with C59 exhibited increased expression
of ACAN and COMP compared to the standard-treated pellets
(Supplementary Fig. 8C, D). Importantly, we also observed that
IFI6 and ISG15, markers for mature-hypertrophic chondrocytes,
were downregulated in the C59-treated pellets, suggesting WNT
inhibition may decrease chondrocyte hypertrophy during
chondrogenesis.
WNT expression with neurogenesis. To determine the expres-
sion patterns of WNTs and to identify the cells responsible for
WNT production, we investigated WNT expression levels in
multiple cell populations of d14 and d28 pellets (Fig. 6E and
Supplementary Fig. 8E; a total of 5224 d14 cells and a total of
3027 d28 cells analyzed, respectively). In TGF-β3-treated pellets,
several canonical WNTs, such as WNT3, WNT3A, and WNT7B,
as well as noncanonical WNTs, including WNT4, were enriched
in the proliferative population (where the neural cells clustered),
while WNT2B and WNT5B could be found in proliferative cells,
chondrocytes, and mesenchyme. We did not detect WNT1,
WNT2, or WNT8 in any specimens. Upon C59 treatment, most
WNTs showed decreased expression, particularly in proliferative
cells. Western blots confirmed that C59-treated pellets had
decreased protein levels of WNT2B, WNT3A, WNT4, and
WNT7B (Fig. 6F). Interestingly, C59 only moderately inhibited
WNT5B. We next plotted these WNT ligands along with neu-
rogenic and chondrogenic markers in pseudotime to investigate
their expression patterns. We observed that WNT2B, WNT3A,
WNT4, and WNT7B clustered with neurogenic markers, whereas
WNT5B was upregulated along with chondrogenic differentia-
tion, implying that individual WNTs may play distinct roles in
regulating chondrogenesis (Fig. 6G).
WNTs alter GAG/DNA and collagen production. As C59 is a
pan-WNT signaling inhibitor, it, therefore, remained unknown
which WNT ligand had the most severe adverse effect on hiPSC
chondrogenesis. To answer this question, we administrated a
variety of WNTs during pellet culture (Supplementary Fig. 9A).
RT-qPCR analysis showed that only WNT7B significantly
decreased chondrogenic markers (SOX9, ACAN, and COL2A1)
and osteogenic marker (COL1A1) when compared to TGF-β3
only pellets (Fig. 7A). Interestingly, the pellets treated with
WNT2B and WNT3A exhibited increased COL2A1, COL1A1,
and COL10A1 expression versus TGF-β3 pellets. However, only
the pellets with WNT3A treatment had a significantly decreased
GAG/DNA ratio compared to the pellets with TGF-β3 only
treatment (Fig. 7B). WNT2B-treated pellets also showed a trend
toward the increasing expression of neurogenic markers (PAX6
and SOX2), although not statistically significant. Furthermore,
WNT2B- and WNT7B-treated pellets had significantly lower
expression of MITF relative to TGF-β3 pellets. We also observed
that WNT ligands may not only regulate their own expression but
may also modulate the expression of other WNT ligands (Sup-
plementary Fig. 9B).
While all pellets had comparable Saf-O staining, WNT
treatment increased off-target cells within the pellets (Fig. 7C).
Furthermore, these off-target cells exhibited lower production of
COL2A1 compared to chondrocytes. Additionally, pellets treated
with WNTs, particularly WNT3A, exhibited higher intensity of
COL1A1 and COL10A1 staining, which was observed near off-
target cells and perichondrium. On the contrary, C59-treated
pellets had low COL1A1 and COL10A1 production, and the
staining was mainly at the perichondrium. Together, these results
indicate that WNTs increased non-chondrogenic cells and
modulated collagen production. The histological images in Fig. 7C
were quantified using a published ImageJ protocol (Supplemen-
tary Fig. 9C)31.
Heterocellular WNT signaling may regulate chondrogenesis.
To investigate which cell populations are the main sources for the
endogenous production of specific WNTs during chondrogenesis,
a heatmap in which the expression of WNT ligands against
multiple cell populations at the d14 timepoint was plotted
(Fig. 7D). We found that 30% of melanocytes expressed WNT2B,
while WNT3A, WNT4, and WNT7B were mainly expressed in
neural cells (Supplementary Fig. 9D). WNT5B was expressed
primarily by chondrocytes (about 10% of the chondrocyte
population) providing a possible explanation for the upregulation
of WNT5B during chondrogenesis. As WNTs are secretory pro-
teins, we next aimed to identify the potential cell populations
receiving WNT signaling based on published lists of
ligand–receptor pairs32. We found that 31.6% of chondrocytes
expressed FZD2, the highest expression of a WNT receptor in
chondrocytes (Fig. 7E). Thus, we created the multicellular sig-
naling for the WNT3A-FZD2 pair and identified that 9.9% of
neural cells expressed WNT3A while more than a third of
chondrocytes (36.1%) were capable of receiving this ligand
(Fig. 7F). In addition, we also observed that although chon-
drocytes were the major contributor to WNT5B production,
melanocytes (30%) might be the main receiving cell type. Fur-
thermore, while 30% of melanocytes may secrete WNT2B, only
1% of chondrocytes expressed FZD4, one of the main WNT2B
receptors (Fig. 7G).
BMP/GDF differential expression after C59 treatment. While
the precise mechanisms of enhanced chondrogenesis remain
to be determined, our CCA analysis showed that six
chondrocyte subpopulations and one mesenchymal population
were conserved between TGF-β3-treated and C59-treated
d14 pellets: (1) HMGB2/CDK1+ proliferating chondrocytes,
(2) UBE2C/CCNB1+ proliferating chondrocytes, (3) LECT1/
EPYC/FRZB+ early mature chondrocytes, (4) ISG15/IFI6/MX1+
mature-hypertrophic chondrocytes, (5) FTL/MT-CO2+ stressed
chondrocytes, (6) BNIP3/FAM162A+ apoptotic chondrocytes,
Fig. 6 CCA analysis reveals that most WNTs, except WNT5B, were secreted by off-target cells. A Three major conserved populations in d14 pellets. A
total of 5224 cells from the d14 pellets with or without C59 treatment was analyzed. B Violin plots of the specific markers for each conserved population.
C C59-treated pellets comprised more chondrocytes and mesenchymal cells. D Expression levels of chondrogenic markers were higher in C59-treated
pellets while expression of neurogenic markers and melanocyte markers was higher in TGF-β3-treated pellets. E Dot plot showing proliferative cells (mainly
neural cells) from TGF-β3-treated pellets had high expression levels of WNT ligands. WNT inhibition largely decreased expression levels of WNTs in cells.
F Western blots confirm that WNT inhibition significantly decreased WNTs in cells at protein levels. *p= 0.026, #p= 0.021, $p= 0.0003, †p= 0.00029,
‡p= 0.021 to its corresponding group. Mean ± SEM. n= 3 per treatment condition. Statistical significance was determined by a two-tailed Student’s t test
for the groups with or without specific WNT inhibition. G Most WNTs were upregulated along the lineage of neural cells, where WNT5B was clustered
with chondrogenic differentiation in TGF-β3-treated pellets. A total of 2148 cells from the TGF-β3-treated d14 pellets was analyzed and used to generate
the heatmap.
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and ACTA2/PRRX1/COL1A1+ mesenchymal cells (Supplemen-
tary Fig. 10A; CCA was performed with a total of 1335 cells
from mesenchymal and chondrocyte populations from d14 TGF-
β3 pellets and with a total of 3047 cells from mesenchymal
and chondrocyte populations from d14 C59 pellets. It is impor-
tant to note that off-target cells (i.e., neural cells and
melanocytes) were exculded from this analysis). Interestingly,
C59 treatment differentially influenced the expression of various
growth factors and receptors in the TGF-β superfamily essential
in regulating chondrogenesis33 (Supplementary Note 1, Supple-
mentary Fig. 10B–E, Supplementary Fig. 11A, B, and Supple-
mentary Fig. 12A, B).
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Discussion
The therapeutic applications of hiPSCs for cartilage regeneration
or disease modeling have been limited by the low-yield of bona
fide chondrocytes, accompanied by off-target populations during
chondrogenic differentiation. Our GRN analysis revealed two
major off-target cell populations, neural cells and melanocytes,
which showed high association with WNT4 and WNT2B sig-
naling, respectively. By building heterocellular signaling models,
we showed that off-target cells were the main source of several
canonical and noncanonical WNT ligands that were implicated in
chondrocyte hypertrophic differentiation. Importantly, inhibition
of WNT and MITF, the master regulator of melanocyte devel-
opment, significantly enhanced homogeneity of hiPSC chon-
drogenesis by decreasing off-target cells, circumventing the need
for prospective sorting and expansion of isolated progenitor cells.
An important finding of this study was the identification of
distinct subtypes of hiPSC-derived chondrocytes, as shown in
depth by the comprehensive transcriptomic profiles of each cell
type at various differentiation stages. We also observed that
inhibition of WNT signaling during chondrogenesis alters gene
expression levels of BMPs/GDFs (e.g., decreasing BMP4 and
BMP7 levels) in chondrocytes, which is consistent with a recent
study demonstrating decreased BMP activity during MSC chon-
drogenesis due to WNT inhibition34. Another intriguing finding
is the discovery of ISG15/IFI6/MX1+ mature-hypertrophic
chondrocytes as, without scRNA-seq, this unique population
has not been reported before. Although the signature genes of this
chondrocyte population (e.g., STAT-1) were generally believed to
be downstream of IFN-related pathways, we did not detect IFN
expression. The high expression of IGFBP3 in ISG15/IFI6/MX1+
chondrocytes may provide an explanation for this observation, as
IGFBP3 can activate STAT-1 expression without the presence of
IFN molecules in chondrogenesis35. In addition, IGFBP3-enri-
ched chondrocytes also had decreased expression of FOS, essen-
tial in driving chondrocytes toward hypertrophy27. It has been
reported that chondrocyte hypertrophy was largely prevented
upon IGFBP3 knockdown in the ATDC5 line36. Thus, low FOS
expression in ISG15/IFI6/MX1+ chondrocytes provides a plau-
sible explanation for their low expression of hypertrophic mar-
kers. Nevertheless, the causal relationship between the dual
function of IGFBP3 in chondrocyte hypertrophy and WNT
inhibition merits further study.
The finding that melanocytes and neural cells were the major
off-target cells implies that some, if not all, progenitors may
acquire the phenotype of neural crest cells, a transient stem cell
population that can give rise to neurons and melanocytes. This
differentiation pathway likely occurs at the Cp stage, where we
first observed cell populations expressing several markers of
neural crest cells. It is likely that the neural crest cells observed in
the current study were also off-target cells (i.e., non-paraxial
mesodermal lineage) generated during the early stages of meso-
dermal differentiation and amplified due to BMP4 treatment at
the Cp stage. It has been reported that the Bmp4-Msx1 signaling
axis inhibits Wnt antagonists such as Dkk2 and Sfrp2 in dental
mesenchyme in mice37, implying that BMP4 treatment may
promote WNT signaling that is essential for the proliferation of
neural crest cells.
Additionally, our sorting results showed that supplementation
of WNT increased, but inhibition of WNT decreased, the pro-
portion of CD146/CD166+ cells, suggesting that WNT signaling
is required to maintain progenitors at the Cp stage. This finding is
in agreement with a recent study showing that WNT3A supports
the multipotency of hMSCs during in vitro expansion38. In our
recent publication using a CRISPR–Cas9-edited reporter hiPSC
line and scRNA-seq techniques, we identified that mesenchymal
cells triple-positive for CD146, CD166, and PDGFRβ, but nega-
tive for CD45, at the Cp stage showed robust chondrogenic
potential but little osteogenic capacity compared to unsorted cells,
suggesting that CD146/CD166/PDGFRβ+ mesenchymal cells
may be a unique Cp population39. However, whether the CD146/
CD166+ progenitor population identified in the current study
functions like MSCs with multilineage potential warrants future
investigation. Furthermore, as distinct subtypes of hiPSC-derived
chondrocytes were defined primarily based on marker genes, the
complete functionality of these subsets requires future
investigation.
Another important contribution of this study is the construc-
tion of the GRN of hiPSC chondrogenesis with the presence of
minimal off-target cells, ensuring the hub genes identified are
truly governing chondrogenic differentiation. In addition to
conventional master TFs such as SOX9, we also identified several
additional hub genes associated with chondrogenesis. For
instance, the expression levels of complement C1q like 1 (C1QL1)
were highly correlated with those of COL2A1 in our model.
C1QL1 encodes a secreted protein with Ca2+ binding sites that
regulate synaptogenesis in neuronal cells40. However, how C1QL1
affects chondrogenesis or if it plays a role in synovial joint
innervation is currently unknown. In addition, our finding of the
melanogenic GRN during hiPSC chondrogenesis suggests an off-
target cell fate decision in differentiation. This result is further
corroborated by the study of Yamashita et al.41 demonstrating the
presence of melanin or lipofuscin on the surface of hiPSC-derived
cartilage pellet using rigorous histological staining. Furthermore,
we also revealed the significant association between WNT2B and
MITF, providing insights into melanogenesis. Indeed, a recent
study proposed genetic variants in WNT2B may serve as a bio-
marker to predict the survival rate of patients with cutaneous
melanoma42. We also identified WNT4 as a hub gene in the GRN
of neurogenesis and observed that WNT3A was enriched in the
cell populations expressing neural markers. These results are
consistent with the previously identified roles for these WNTs in
promoting forebrain development43,44.
Heterogenous multicellular signaling models indicate that
although most WNTs were produced by off-target cells, these
ligands may signal through chondrocytes. It is well recognized
that WNT signaling not only blocks SOX9 expression in limb bud
mesenchymal cells but also regulates chondrocyte maturation,
driving them toward hypertrophy45,46. In agreement with these
findings, hiPSC-derived chondrogenic pellets treated with indi-
vidual WNTs exhibited increased COL10A1 staining. We also
Fig. 7 Heterogenous multicellular WNT signaling models. A, B RT-qPCR and GAG/DNA ratios of pellets treated with various WNTs during pellet culture.
Different letters are significantly different from each other (p < 0.05). Mean ± SEM. n= 3–4 pellets per group. Statistical significance was determined by
one-way ANOVA with Tukey’s post hoc test. C WNT treatment increased infiltration of off-target cells (pink arrowheads and white dashed lines) into the
pellets, decreased COL2A1 staining, but increased COL1A1 (yellow arrowheads) and COL10A1 staining in the pellets. The pellets with C59 treatment
exhibited homogenous COL2A1 staining and decreased COL1A1 and COL10A1 staining. Scale bar= 0.2 mm. The experiment was performed twice with
similar results. D Heatmap showing distinct expression levels of various WNTs in various cellular subpopulations in d14 TGF-β3-treated pellets. A total of
2148 cells from the TGF-β3-treated d14 pellets was analyzed and used to generate the heatmap. E Percentage of the cells expressing WNT3A and its
putative receptors in d14 TGF-β3-treated pellets. F, G Heterogenous multicellular signaling models in d14 TGF-β3-treated pellets.
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demonstrated that blocking endogenous WNT signaling sig-
nificantly improved chondrogenesis in hMSCs. These findings
reveal the potential modulatory effects of off-target cells on
chondrocytes through the WNT signaling pathway, indicating
that inhibition of WNT has dual beneficial effects on hiPSC
chondrogenesis as it not only removes off-target cells but also
prevents chondrocyte hypertrophy.
These findings not only identify the mechanisms regulating the
heterogeneity in hiPSC chondrogenesis but, more importantly,
provide an enhanced chondrogenic differentiation protocol cap-
able of generating homogenous chondrocytes by removing off-
target cells without cell sorting. Furthermore, this protocol has
been validated in multiple unique lines, demonstrating its
robustness and efficiency in deriving chondrocytes from hiPSCs.
We also established a comprehensive map of single-cell tran-
scriptome profiles and GRNs governing cell fate decisions during
hiPSC chondrogenesis. These findings provide insights into
dynamic regulatory and signaling pathways orchestrating hiPSC
chondrogenesis, thereby advancing a further step of cartilage
regenerative medicine toward therapeutic applications. This
approach also provides a roadmap for the use of single-cell
transcriptomic methods for the study and optimization of other
in vitro or in vivo differentiation processes.
Methods
Key resources including antibodies, growth factors, culture reagents are listed in
Supplementary Table 3.
hiPSC lines and culture. Three distinct hiPSC lines were used in the current study:
STAN, ATCC, and BJFF. STAN line was purchased from WiCell (#STAN061i-164-
1), ATCC line was acquired from ATCC (#ATCCACS-1019), and BJFF was
obtained from the Genome Engineering and iPSC Core at Washington University
in Saint Louis. All three lines were reprogrammed by Sendai virus from human
foreskin fibroblasts and confirmed to be karyotypically normal and mycoplasma
free. STAN and BJFF hiPSCs were maintained on vitronectin coated 6-well plates
(Thermo Fisher Scientific, #A31804) in Essential 8 Flex medium (Thermo Fisher
Scientific, #A2858501). ATCC hiPSCs were cultured on CellMatrix Basement
Membrane Gel coated 6-well plates (ATCC, #ACS3035) in Pluripotent Stem Cell
SFM XF/FF medium (ATCC, #ACS3002). Cells were fed daily and passaged with
ReLeSR (STEMCELL Technologies, #05872). All hiPSC lines were maintained
below passage 30.
hMSCs and culture. Discarded and deidentified waste tissue from the iliac crests of
adult bone marrow transplant donors was collected in accordance with the insti-
tutional review board of Washington University in Saint Louis. Human bone
marrow-derived MSCs (hMSCs) were isolated by their physical adherence to
plastic culture vessels47. Cells were expanded and maintained in an expansion
medium consisting of DMEM-low glucose (Thermo Fisher Scientific, #11885092),
1% penicillin/streptomycin (P/S, Thermo Fisher Scientific, #15140-122), 10%
lot-selected FBS (Atlanta Biologicals, #S11550), and 1 ng ml−1 basic fibroblast
growth factor (FGF) (R&D Systems, #233-FB). Three individual donors
were used as biologic replicates in subsequent experiments (Supplementary
Table 4).
Mesodermal differentiation. hiPSCs were induced into mesodermal differentia-
tion in monolayer at 40% confluency7. Each day, cells were rinsed with a wash
medium consisting of 50% IMDM GlutaMAX (IMDM, Fisher Scientific,
#31980097) and 50% Ham’s F12 Nutrient Mix (F12, Fisher Scientific, #31765092)
to remove the previous medium. hiPSCs were then fed daily to sequentially drive
mesodermal differentiation similar to those identified in embryonic development
with various sets of growth factors and small molecules supplemented in meso-
dermal differentiation medium consisting of equal parts of IMDM and F12 with
1% chemically defined lipid concentrate (Gibco), 1% insulin/human transferrin/
selenous acid (ITS+, Corning, #354352), 1% P/S (Thermo Fisher Scientific,
#15140-122), and 450 μM 1-thioglycerol (Sigma–Aldrich, #M6145). Cells were
induced to the anterior primitive streak with 30 ng ml−1 of Activin A (R&D Sys-
tems, #338-AC), 4 µM CHIR99021 (Stemgent, #04-0004), and 20 ng ml−1 human
FGF-2 (R&D Systems, #233-FB-025/CF) for 24 h. On the second day, cells were
driven to paraxial mesoderm with 2 µM SB-505124 (SB5; Tocris, #3263), 3 µM
CHIR99021, 20 ng ml−1 human FGF-2, and 4 µM dorsomorphin (DM; Stemgent,
#04-0024). Then, cells were treated with 2 µM SB5, 4 µM DM, 1 µM Wnt-C59
(C59; Cellagent Technology, #C7641-2s), and 500 nM PD173074 (Tocris, #3044) to
become early somite on the third day. For the fourth through sixth days, cells were
driven to the sclerotome with daily feedings of 2 µM purmorphamine (Stemgent,
#04-0009) and 1 µM C59. Finally, for six days, cells were driven to the Cp stage
with 20 ng ml−1 of human bone morphogenetic protein 4 (BMP4; R&D Systems,
#314-BP-010/CF) daily (Supplementary Fig. 1A).
At each stage, cells were dissociated using TrypLE (Gibco, #12604013) at 37 °C
for 3 min followed by adding an equal part of neutralizing medium consisting of
DMEM/F-12, GlutaMAXTM (DMEM/F12; Thermo Fisher Scientific, #10565042)
with 10% FBS (Atlanta Biologicals) and 1% P/S. The dissociated cells were either
used for bulk RNA-seq, scRNA-seq, chondrogenic differentiation, or fluorescence-
activated cell sorting (FACS) as appropriate.
Chondrogenic differentiation. Cells dissociated at the Cp stage were resuspended
at 5 × 105 cells per mL in chondrogenic medium consisting of DMEM/F-12, 1% FBS,
1% ITS+, 55 µM β-mertcaptoethanol, 100 nM dexamethasone (DEX; Sigma-Aldrich,
#D4902), 1% NEAA (Gibco, #11140050), 1% P/S, 10 ngml−1 human transforming
growth factor-beta 3 (TGF-β3; R&D Systems, #243-B3-010), 50 μgml−1 L-ascorbic
acid 2-phosphate (ascorbate; Sigma-Aldrich, #A8960), and 40 μg ml−1 L-Proline
(proline; Sigma-Aldrich, #P5607). Cells were then centrifuged for 5 min at 300 × g to
form a pellet. Chondrogenic pellets were cultured at 37 °C for up to the timepoints
required for various experiments.
On the day of collection for bulk RNA-seq experiments, 3–4 pellets per
experimental group were pooled together and washed once with phosphate-
buffered saline (PBS), snap-frozen in 300 µl of Buffer RL (Norgen Biotek), and
stored at −80 °C until processing for RNA extraction. At harvesting time points for
scRNA-seq experiments, 6–8 pellets per experimental group were pooled and
digested with 0.04% Type II collagenase solution in DMEM/F12 for 1 h. Cells were
washed once with PBS, resuspended in standard freezing medium, and stored in
liquid nitrogen until needed.
C59 and ML329 treatment for WNT and MITF inhibition. For C59 treatment for
WNT inhibition during chondrogenesis, pellets were treated with either 10 ng ml−1
TGF-β3 (control group) or a combination of 10 ng ml−1 TGF-β3 and 1 μM C59 in
a chondrogenic medium from d0 to d42 as appropriate. For C59 and ML329
treatment (ML, Axon Medchem, HY-101464) for WNT and MITF inhibition
during chondrogenesis, pellets were treated with either 10 ng ml−1 TGF-β3 (con-
trol group), a combination of 10 ng ml−1 TGF-β3 and 1 μM ML, a combination of
10 ng ml−1 TGF-β3 and 1 μM C59, or a combination of 10 ng ml−1 TGF-β3, 1 μM
ML and 1 μM C59 in chondrogenic medium from d0 to d42 as appropriate.
WNT ligands treatment during chondrogenesis. For WNT ligands treatment
during chondrogenesis, pellets were treated with either 10 ng ml−1 TGF-β3
(control group) or a combination of 10 ng ml−1 TGF-β3 and 100 ng ml−1 indivi-
dual WNT ligand (WNT2B, WNT3A, WNT4, WNT5B, or WNT7B, all from R&D
system) in chondrogenic medium from d0 to d42 as appropriate. For WNT ligands
treatment during the Cp stage, cells were supplemented with either 20 ng ml−1
BMP4 (R&D Systems, #314-BP-010) alone (control group), a combination of
20 ng ml−1 BMP4 and 1 μM C59, or a combination of 20 ng ml−1 BMP4 and
100 ng ml−1 WNT3A (R&D Systems, #5036-WN-010) in mesodermal differ-
entiation medium from d7 to d12.
Animal experiments. All animal procedures were approved by the Institutional
Animal Care and Use Committee (IACUC) at Washington University in Saint
Louis. Male NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, #005557, Jackson
laboratory) at age of 18–20 weeks old were used for human xenograft implantation
in the dorsal region (subcutaneous) or in osteochondral defects in the knee joints of
mice. Mice were housed under a 12 h light/12 h dark cycle with ambient tem-
perature and humidity. NSG mice were anesthetized with 3% isoflurane in oxygen
for all surgical procedures. For subcutaneous implantation, the skin was shaved and
sterilized over the implantation site using standard sterile techniques. A mid-
scapular incision was made, and a hemostat was inserted into the skin incision to
create a pocket for implantation. A d14 hiPSC chondrogenic pellet was then
inserted into the pockets. The incision of the skin was closed with 8-0 suture with
taper point (PolysorbTM, Covidien, #L-2800). Tissue adhesive was applied to the
skin wound area. For implantation in osteochondral defects in the knee, a 3 mm
long medial parapatellar incision was made in the left hindlimb, and the knee joint
was exposed via lateral dislocation of the patella. An osteochondral defect (1 mm in
diameter and 1 mm in depth) in the trochlear groove of the femur was created by a
1 mm micro bone drill (Roboz, #RS-6300A). All debris was removed by sterile PBS
washes. Mild hemorrhage from the fat pad was controlled by epinephrine 1:1000
(International Medication Systems, #491590) followed by sterile PBS wash. A d14
hiPSC chondrogenic pellet was implanted into the defect, and the patella was
repositioned to its original anatomical location. Mice with osteochondral defects
that did not receive pellet implantation were used as a control group. After
implantation, the subcutaneous layer and skin were closed with 8-0 suture with a
tapered point followed by the application of tissue adhesive to the skin wound area.
After surgery, the mice were allowed to move freely within their cages. After 14 and
28 days post implantation, mice were sacrificed for pellet harvest for histological
analysis.
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RNA isolation, library preparation, and bulk RNA-seq. To determine tran-
scriptome profiles over the course of differentiation, three hiPSCs lines (ATCC,
BJFF, and STAN) as biological replicates at various differentiation stages (6
mesodermal and 5 chondrogenic stages per cell line; i.e., total 33 samples) were
collected for bulk RNA-seq. Cell samples were thawed on ice, and pellet samples
were homogenized with zirconia beads (BioSpec Products, # 11079110zx) and a
miniature bead beater. RNA was then isolated from all samples using the Total
RNA Purification Kit according to the manufacture’s protocol (Norgen Biotek,
#37500). RNA was eluted in 20 μl of diethylpyrocarbonate-treated water. The
quality and quantity of RNA from each sample was evaluated by RNA Analysis
ScreenTape (Agilent, #5067-5576) on a bioanalyzer (Agilent 4200 Tapestation).
Only samples with a RIN value larger than 0.8 were submitted to the Genome
Technology Access Center (GTAC sequencing core) at Washington University in
St. Louis for library preparation and bulk RNA-seq. Libraries were prepared using
TruSeq Stranded Total RNA with Ribo-Zero Gold kit (Illumina). Sequencing was
performed on a HiSeq2500 instrument (Illumina) (1 × 50 bp reads) with a
sequencing depth of 30 million reads per sample.
Preprocessing of bulk RNA-seq data. Reads were processed using an in-house
pipeline and open-source R packages as previously described48. Raw reads were
first trimmed using Cutadapt to remove low-quality bases and reads49. After
trimming, processed reads were aligned to the human reference genome GRCh38
(version 90) by STAR50, and the number of aligned reads to each annotated genes
or transcripts (GENCODE v21) was performed using featureCounts from the
Subread package (v1.4.6)51.
DEGs and GO enrichment analysis and of bulk RAN-seq data. After quality
control, un-normalized gene counts were read into the DESeq2 R package by
DESeqDataSetFromMatrix function as instructed by the package tutorial52. Genes
that were expressed by less than ten cells were then removed. Next, we used DESeq
and results functions which implement Wald test in DESeq2 to determine the
DEGs between two consecutive differentiation stages. In this process, the estima-
tion of size factors (i.e., controlling for differences in the sequencing depth of the
samples), the estimation of dispersion values for each gene, and fitting a general-
ized linear model were performed. The gene counts were also averaged from three
hiPSC lines. Top 20 DEGs between two consecutive stages were selected and
visualized using ComplexHeatmap R package. To observe the temporal expression
of a given gene for each hiPSC line, the count matrix was regularized-logarithm
transformed via rlog function first, and we used plotCounts function in DESeq2 to
visualize the expression pattern of the gene. Furthermore, regularized-logarithm
transformed counts were also used for PCA, and PCA plots were visualized by
ggplot function in ggplot2 R package53.
We next performed GO enrichment analysis of the genes in mesodermal and
chondrogenic stages using GAGE R package (Generally Applicable Gene-set/
Pathway Analysis), whose algorism evaluates the coordinated up- or down-
differential expression over gene sets defined by GO terms13. Significantly
upregulated GO terms with their associated p values in biological process,
molecular function, and cellular component were plotted by GraphPad Prism
(version 8.0; GraphPad Software). Furthermore, GAGE analysis also reveals that
134 out of 205 genes defined by GO term cartilage development (GO:0051216)
were significantly increased during our differentiation process. Thus, a heatmap
was generated to investigate the expression levels of these genes at various stages
using ComplexHeatmap R package54.
10× chromium platform scRNA-seq. Cells were thawed at 37 °C and resuspended
in PBS with 0.04% bovine serum albumin at a concentration of 2000 cells per μl.
Cell suspensions were submitted to the GTAC sequencing core at Washington
University in St. Louis for library preparation and sequencing. In brief, 10,000 cells
per sample were loaded on a Chromium Controller (10× Genomics) for single
capture. Libraries were prepared using Single Cell 3′ Library & Gel Bead Kit v2
(#120237 10× Genomics) following the manufacture’s instruction. A single cell
emulsion (Gel Bead-In-EMulsions, GEMs) is created by making barcoded cDNA
unique to each individual emulsion. A recovery agent was added to break GEM and
cDNA was then amplified. A library is produced via end repair, dA-tailing, adapter
ligation, post-ligation cleanup with SPRIselect, and sample index PCR. The quality
and concentration of the amplified cDNA were evaluated by Bioanalyzer (Agilent
2100) on a High Sensitivity DNA chip (Agilent, #5065-4401). The only cDNA with
an average library size of 260–620 bp were used for sequencing. Sequencing was
performed by Illumina HiSeq2500 with the following read length: 26 bp for Read1,
8 bp for i7 Index, and 98 bp for Read2. We generally acquired ~180 million reads
per library (sample). A species mixing experiment (mouse adipose stem cells and
human iPSCs, 1:1 mixture) was also performed prior to running on the actual
sample to ensure good quality of single-cell capture (i.e., cell doublet rate < 5%).
Preprocessing of scRNA-seq data. Paired-end sequencing reads were processed
by Cell Ranger (10× Genomics software, version 2.0.0). Reads were aligned to the
GRCh38 (version 90) for genome annotation, demultiplexing, barcode filtering,
and gene quantification. Cell Ranger also removes any barcode that has less than
10% of the 99th percentile of total unique molecular identifiers (UMI) counts per
barcode as these barcodes are considered to be associated with empty droplets.
After this quality control, gene barcode matrices for each sample were generated by
counting the number of UMIs for a given gene (as a row) in the individual cell (as a
column). For each sample, ~1300–2500 cells were captured.
Unsupervised clustering analysis and annotation. To assess the difference in the
composition of cell populations, we performed global unsupervised clustering
analysis for our scRNA-seq datasets. First, gene barcode matrices were input into
the Seurat R package (version 2.4)15. We then removed the low-quality cells with
less than 200 or more than 7000 detected genes or if their mitochondrial gene
content was more than 5%. Note that the cutoff criteria were adjusted in few cases
due to the sequencing depth and the variations in mitochondrial gene content from
datasets. Genes that were detected in less than three cells were filtered out. After
filtering out low-quality cells or cell doublets, the gene expression was then natural
log-transformed and normalized for scaling the sequencing depth to 10,000
molecules per cell. Next, to reduce the variance introduced by unwanted sources,
we regressed out variation in gene expression driven by cell cycle stages and
mitochondrial gene expression with vars.to.regress argument in function ScaleData
in Seurat. We then used the FindVariableGenes function in Seurat to identify highly
variable genes across cells for downstream analysis. These steps resulted in (1) a
total of 8547 cells with an average of 1882 highly variable genes from stages of
hiPSCs, Sclerotome, and Cp stages, (2) a total of 10,648 cells with an average of
2061 highly variable genes from stages of TGF-β3-treated pellets (d1, d3, d7, d14,
d28, and d42), and (3) total 7997 cells with average 1886 highly variable genes from
TGF-β3+C59-treated pellets (d7, d14, d28, and d42) for downstream analysis.
Detailed cell numbers that passed quality control steps for each stage are listed in
Supplementary Table 5. Dimensionality reduction on the data was then performed
by computing the significant principal components on highly variable genes. We
then performed unsupervised clustering by using the FindClusters function in
Seurat with the resolution argument set to 0.6, and clusters were then visualized
in a tSNE plot55.
DEGs among each cell cluster were determined using the FindAllMarkers
function in Seurat. DEGs expressed in at least 25% of cells within the cluster and
with a fold change of more than 0.25 in natural log scale were considered to be
marker genes of the cluster. To determine the biological functions of the marker
genes from a given cluster, we performed GO enrichment analysis by using The
DAVID Gene Functional Classification Tool (http://david.abcc.ncifcrf.gov; version
6.8)56. By comparing these unique biological GO terms with existing RNA-seq
datasets and the literature, we were able to annotate cell clusters. In addition, the
top 10 enriched GO terms from the biological function category with associated p
values were visualized GraphPad Prism (version 8.0; GraphPad Software).
Cell cycle analysis of scRNA-seq data. Cell cycle scoring function in Seurat was
used to determine a cell cycle score on each cell according to its gene expression of
G2/M phase (54 genes) and S phase (43 genes) markers57. Based on this scoring
system, fractions of each cell cluster with a given cell cycle score in total cell
population were computed.
CCA for integrated analysis of multiple scRNA-seq datasets. To compare cell
types and to identify their associated DEGs between distinct experimental condi-
tions such as batch effect, C59 treatment, or differentiation stages (i.e., time points),
we applied CCA, a computational strategy implemented in Seurat for integrated
analysis of multiple datasets. First, the top 1000 highly variable genes from each
dataset were selected. We then use the RunCCA function or RunMultiCCA func-
tion (if more than two datasets) to identify common sources of variation resulting
from experimental conditions and to merge the multiple objects into a single
dataset. We next determined the top principal components of the CCA by
examining a saturation in the relationship between the number of principal
components and the percentage of the variance explained using the MetageneBi-
corPlot function. By using selected top principal components, we aligned the CCA
subspaces with the AlignSubspace function, which returns a new dimensional
reduction matrix allowing for downstream clustering and DEG analyses. DEG
analysis was performed on the cells from different datasets but grouped in the same
cluster (i.e., conserved cell types between two conditions) after CCA alignment.
The methods for cell clustering, identification of conserved cell types and DEGs, as
well as annotation of cell clusters were similar to the ones mentioned previously.
DEGs in each conserved cell type in response to differentiation stages or C59
treatment were visualized by ComplexHeatmap R package54. In some cases, genes
of interest such as WNTs and various lineage markers were also visualized using
the FeatureHeatmap and DotPlot function in Seurat.
Pseudotemporal ordering and lineage trajectories. We used the Monocle2 R
package to reconstruct differentiation trajectories by computing and ordering the
sequence of gene expression changes of the cells collected from different time
points in an unsupervised manner16,58. First, scRNA-seq datasets from different
timepoints underwent several quality control steps as mentioned previously. These
multiple scRNA-seq datasets were then merged into one single object using the
MergeSeurat function in Seurat. The merged matrix was then converted into a
Monocle object using importCDS and newCellDataSet functions in Monocle2. We
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then identified a set of DEGs between the cells collected at the beginning of the
process to those at the end using differentialGeneTest function with argument qval
< 0.01 in Monocle. The dimensions of the dataset were then reduced using the first
two principal components with the “DDRTree” method. Next, we used orderCells
function to order the cells based on the selected DEGs and the trajectory of the cells
was visualized by the plot_cell_trajectory function in Monocle. The temporal
expression of the gene of interests was visualized using the plot_genes_in_pseu-
dotime function in Monocle. Additionally, to observe dynamic changes in the
expression levels of the genes that were branch dependent (i.e., along with specific
lineage), we used plot_genes_branched_heatmap function in Monocle to construct
a special type of heatmap in which genes that had similar lineage-dependent
expression patterns were clustered together.
WGCNA reconstruction of GRNs and hub genes. We used WGCNA, an algo-
rithm implemented in the WGCNA R package, to reconstruct GRNs and to
identify their associated hub genes that regulate cell differentiation19. First, the
dataset of interest (e.g., a given time point) created in Seurat was converted into a
plain matrix for a given gene (in the column) in an individual cell (in a row). The
dataset was then cleaned by removing cells with too many missing values using the
goodSamplesGenes function in WGCNA. Next, we used the pickSoftThreshold
function in WGCNA to determine the proper soft-thresholding power (β) that fits
the criterion of the approximate scale-free topology of the network, and an adja-
cency matrix was then built with soft-thresholding power of eight in our study.
Hierarchical clustering and GRN were constructed by using blockwiseModules
function with arguments TOMType set to unsigned, networkType set to sign, and
mergeCutHeight set to 0.25 in WGCNA. Modules containing genes that were
highly associated with each other were identified in this process. Gene lists of
interesting modules were extracted and submitted to DAVID for GO term analysis
to retrieve their biological process and molecular functions. We then identified TFs
and TF regulators from the genes based on the GO terms in molecular functions.
We then selected the top 100 genes that had the highest weight (i.e., high corre-
lation coefficient) connected to a given TF or TF regulator. Finally, the GRN based
on these TFs and TF regulators then underwent cluster analysis using community
cluster (GLay)59 and was then visualized using Cytoscape60. Hub genes for each
GRN were identified as genes with high weight (summed correlation coefficients),
high degree (summed connectivity, i.e., total numbers genes connected to this
specific gene), and high betweenness centrality (BC) measure of the network. The
hub gene of a given GRN was visualized by ComplexHeatmap R package54.
Multicellular signaling and ligand-receptor models. To investigate the
ligand–receptor interaction in heterogenous multicellular signaling systems, we
used a list comprising 2557 human ligand–receptor pairs curated by Database of
Ligand–Receptor Partners, IUPHAR, and Human Plasma Membrane
Receptome32,61. We first quantified the percentage of the cells (i.e., neural cells,
melanocytes, and chondrocytes) that expressed a specific WNT ligand and its
associated frizzled (FZD) receptors using scRNA-seq datasets. To ensure the ligand
and receptors are uniquely expressed, we required that their expression in fold
change needs to more than 0.25 on a natural log scale. We then used Circlize R
package to visualize the directions of the signaling in the cell type based on con-
nections of ligand–receptor pairs62.
RNA fluorescence in situ hybridization (RNA-FISH). To validate scRNA-seq
findings and to visualize the spatial distribution of WNTs and COL2A1 within
pellets, we performed RNA-FISH for WNT3A, WNT4, and COL2A1 expression.
d28 pellets with or without C59 treatment were harvested (n= 3 time point) and
snap-frozen in liquid nitrogen. Pellets were cryo-sectioned at 10 μm thick and fixed
using 4% paraformaldehyde in PBS on ice for 10 min. Sample pre-treatment and
RNA probe hybridization, amplification, and signal development were performed
using the RNAscope Multiplex Fluorescent Reagent Kit v1 (Advanced Cell Diag-
nostics, #320850) following the manufacturer’s instruction. Samples were imaged
with multichannel confocal microscopy (Zeiss LSM 880). Tiled images with Z-
stacks were taken at 20× magnification to capture the entire pellet. Maximum
intensity projection, a process in which the brightest pixel (voxel) in each layer
along Z direction is projected in the final 2D image, was performed using Zeiss Zen
Blue (version 2.5).
FACS for progenitors. Cells at the Cp stage with the treatment of BMP4, a
combination of BMP4 and WNT3A, or a combination of BMP4 and C59 were
dissociated and resuspended in FACS Buffer (PBS−/− with 1% FBS and 1%
penicillin/streptomycin/fungizone (P/S/F; Gibco) at approximately 40 × 106 cells
per ml. The cells were treated with Human Tru Stain FC XTM (BioLegend,
#422302) for 10 min at room temperature. Approximately, 10,000 cells in 100 µl
were used for each compensation. Cells were labeled with appropriate antibodies
including their associated isotype control (FITC-CD45, #304006; PE/Cy7-CD146,
#361008; PE-CD166, #343904, all from BioLegend). Cells were incubated for 30
min at 4 °C and washed with FACS buffer twice. Samples were resuspended in a
sorting medium consisting of DMEM/F12 with 2% FBS, 2% P/S/F, 2% HEPES
(Gibco), and DAPI (BioLegend, #422801) at 4 × 106 cells per ml and filtered
through a 40 µm cell strainer. Cells were stored on ice prior to sorting. Five
microliters of all antibodies were used per million cells in 100 µl staining volume;
10 µl of Tru Stain FC XTM was used per million cells in 100 µl staining volume.
DAPI was used at 3 µM. An Aria-II FACS machine was used to compensate for the
color overlapping and to gate the samples. Data were analyzed using FlowJo
software (version 10.5.3).
Histology. Pellets were collected in 10% neutral buffered formalin for fixation for
24 h. Pellets were then transferred to 70% ethanol, dehydrated, and embedded in
paraffin wax. Pellet blocks were sectioned at 8 µm thickness and stained for pro-
teoglycans and cell nuclei according to the Safranin-O and hematoxylin standard
protocol.
Immunohistochemistry. Histologic sections (8 μm thick) of the pellets were rinsed
with xylenes three times and rehydrated before labeling. Antigen retrieval was
performed with 0.02% proteinase K for 3 min at 37 °C for COL2A1 and COL6A1
and with pepsin for 5 min at room temperature for COL1A1 and COL10A1 fol-
lowed by peroxidase quench then serum blocking for 30 min at room temperature.
Samples were labeled for 1 h with the primary antibody against COL1A1 (1:800
Abcam #90395), COL2A1 (1:10 Iowa #II-II6B3-s), COL6A1 (1:1000 Fitzgerald
#70F-CR009X), and COL10A1 (1:200 Sigma #C7974) and for 30 min with the
secondary antibody goat anti-mouse (1: 500, Abcam #97021) or goat anti-rabbit
(1:500 Abcam #6720) as appropriate. Histostain Plus Kit (Sigma, #858943) was
then used for enzyme conjugation for 20 min at room temperature followed by
AEC (ThermoFisher, #001111) for 2.5 min (COL2A1 and COL6A1) or 2 min
(COL1A1 and COL10A1) at RT. Finally, samples were counterstained with
hematoxylin to reveal cell nuclei for 45 sec and mounted with Vector Hematoxylin
QS (Vector lab, #H3404). Images were taken by the Olympus VS120 microscope
(VS120-S6-W).
Biochemical analysis of cartilaginous matrix production. Pellets were rinsed
with PBS after chondrogenic differentiation and digested at 65 °C overnight in 200
µl papain solution consisting of 125 μg ml−1 papain (Sigma, P4762), 100 mM
sodium phosphate, 5 mM EDTA, and 5 mM L-cysteine hydrochloride at 6.5 pH.
Samples were stored at −80 °C before thawing to measure double-stranded DNA
by Quant-iT PicoGreen dsDNA Assay Kit (ThermoFisher, #P11496) and glyco-
saminoglycans (GAG) by the 1,9-dimethylmethylene blue assay at 525 nm wave-
length63. GAG content, as calculated based on the standard curve, was normalized
to double-stranded DNA content to obtain the GAG/DNA ratio.
RT-qPCR. RNA of the pellets was isolated using the Total RNA Purification Kit
according to the manufacture’s protocol (Norgen Biotek, #37500). Reverse tran-
scription of the RNA was performed using SuperScript VILO Master Mix (Thermo
Fisher, # 11755050). Fast SYBR Green Master Mix (Thermo Fisher, # 4385614) was
used for reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
according to the manufacturer’s instructions on the QuantStudio 3 (Thermo
Fisher). Gene expression was analyzed using the ΔΔCT method relative to undif-
ferentiated hiPSCs with the reference gene TATA-box-binding protein (TBP).
Sequences of primers are listed in Supplementary Table 6.
Western blots. To examine the effect of C59 on WNT inhibition in the pellets at
protein levels, Western blot analysis was performed on d28 pellets with or without
C59 treatments. Six to eight pellets per experimental group were pooled and
digested with 0.04% Type II collagenase solution in DMEM/F12 for 1 h. Cells were
washed once with PBS and lysed in RIPA buffer (Cell Signaling Technology,
#9806S) with protease inhibitor (ThermoFisher, #87786) and phosphatase inhibitor
(Santa Cruz Biotechnology, #sc-45044). Protein concentration was measured using
the BCA Assay (Pierce). Ten micrograms of proteins for each well were separated
on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels with pre-
stained molecular weight markers (Bio-Rad, 161-0374) and transferred to a poly-
vinylidene fluoride (PVDF) membrane. The PVDF membrane blots were incubated
overnight at 4 °C with the following primary antibodies: anti-WNT2B (1:350,
Abcam, ab178418), anti-WNT3A (1:1000, Abcam, ab81614), anti-WNT4 (1:500,
Abcam, ab91226), anti-WNT5B (1:500, Abcam, ab93134), anti-WNT7B (1:2000,
Abcam, ab155313) and anti-GAPDH (1:30000, Proteintech 60004-1-Ig) for loading
control, respectively. Affinity purified horseradish peroxidase (HRP)-linked goat
anti-rabbit IgG secondary antibody (1:3000, Cell Signaling, #7074) or horse anti-
mouse IgG secondary antibody (1:3000, Cell Signaling, #7076) was added and
incubated for 45 min at room temperature. Immunoblots were imaged and ana-
lyzed using the iBright FL1000 Imaging System (Thermo Fisher). After the WNT
proteins were imaged, the blots were then stripped by incubating with restore plus
Western blot stripping buffer (ThermoFisher Scientific) at room temperature for
15 min. A full scan of all unprocessed Western blots is provided in the Source
Data File.
Statistical analysis. All data were presented as mean ± SEM. Analyses were per-
formed using SPSS Statistics (version 25) with significance reported at the 95%
confidence level. In the current study, the number of pellets per group or treatment
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condition is technical replicates, while the number of mice per group are biological
replicates.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
We acquired RNA-seq datasets of human primary chondrocytes from a previously
published study (NIH Gene Expression Omnibus (GEO) accession number GSE106292)14,
in which embryonic hind limb bud chondrocytes (age: 6 weeks, n= 2), adolescent knee
chondrocytes (age: 17 weeks, n= 2), adult knee chondrocytes (age: 18–60 years, n= 2), and
growth plate chondrocytes (age: 14 weeks, 15 weeks, and 18 weeks, n= 1 per age). For the
datasets obtained from the previously mentioned study, gene expression counts were
averaged if there were more than two samples of the same age. We also harvested
chondrocytes from human costal cartilage and performed bulk RNA-seq on these samples
(age: ~70 years, n= 3). However, it was challenging to collect rib cartilage from young
healthy donors; thus, aged 70-year-old costal cartilages were used. To compare the
difference between the phenotypes of chondrocytes derived from hiPSCs and hMSCs, we
also used bulk RNA-seq datasets of hMSC chondrogenesis from our recent study (GEO
accession number GSE109503)47. For the present study, our bulk RNA-seq and scRNA-seq
datasets are available on GEO accession number GSE160787. Source data are provided with
this paper.
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